Once the diagnostic suspicion of acute promyelocytic leukemia (APL) has been raised, international guidelines recommend prompt initiation of tailored therapy and supportive care, while awaiting for genetic confirmation of the diagnosis, and the identification of the specific PML/ RARA isoform by reverse transcriptase polymerase chain reaction (RT-PCR). Depending on the PML break point, usually located within intron 6, exon 6, or intron 3, different PML/RARA transcript isoforms may be generated, that is, long (bcr1), variant (bcr2), and short (bcr3), respectively. We report here the characterization of three APL cases harboring atypical PML/RARA transcripts, which were not clearly detectable after standard RT-PCR amplification. In all three cases, clinical, morphological, and immunophenotypic features were consistent with APL. Direct sequencing allowed the identification of atypical break points within the PML and RARA genes.
Then, we designed a patient-specific quantitative real-time PCR for the atypical transcripts, which allowed for specific quantitative evaluation of minimal residual disease (MRD) during follow-up. Despite the rarity of APL cases with an atypical PML/RARA fusion, our study indicates that an integrated laboratory approach, employing several diagnostic techniques is crucial to timely diagnose APL. This approach allows prompt initiation of specific targeted treatment and reliable MRD monitoring in atypical APL cases.
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| INTRODUCTION
Acute promyelocytic leukemia (APL) is characterized by the reciprocal t (15;17)(q22;q12) translocation, resulting in the PML/RARA fusion gene. 1 Depending on the PML break point, usually located in intron 6, exon 6, or intron 3, different PML/RARA transcripts may be generated, including the long (bcr1), variant (bcr2), and short (bcr3) isoforms, respectively. 2 The long and short isoforms are detected in 95% of APL cases, whereas only 5% of cases harbor a variant transcript. In contrast, RARA break points are always located within intron 2. 3 Once the diagnostic suspicion of APL has been raised, international guidelines recommend prompt initiation of tailored therapy and proper supportive care waiting for diagnostic confirmation through the rapid detection of the PML/RARA fusion gene. 4 Reverse transcriptase polymerase chain reaction (RT-PCR) represents the gold standard for genetic confirmation of APL, as it allows the identification of the specific PML/RARA isoform. 5 Other techniques, including conventional karyotype and fluorescence in situ hybridization can be used for diagnostic confirmation. During follow-up, isoformspecific quantitative real-time PCR (Q-RT-PCR) allows assessment of response during therapy, minimal residual disease (MRD) monitoring, and eventually detection of molecular relapse. 6, 7 In addition to the typical bcr1, bcr2, and bcr3 rearrangements, Total RNA was extracted from Ficoll-Hypaque isolated bone marrow (BM) mononuclear cells collected at diagnosis, using standard procedures. 17 RT-PCR for PML/RARA detection was carried out using standard protocols. 5 In selected patients (UPN 5, 31, 43), Q-RT-PCR analysis using the primer/probe set developed within the Europe Against Cancer (EAC) program 6, 7 was performed at APL diagnosis, as well as during follow-up. PML/RARA levels were defined as the normalized values of PML/RARA transcript per 10 4 ABL1 transcript. 6 Conventional karyotyping was performed on BM diagnostic aspirates after short-term culture and analyzed after G-banding. The description of the karyotype was according to the International System for Human Cytogenetic Nomenclature. 18 Immunophenotype was studied on BM diagnostic samples on a FACScalibur flow cytometer using standard protocol and a panel of antibodies as described previously. 19 
| Direct sequencing and patient-specific Q-RT-PCR assay
PCR products were purified using the QIAquick gel extraction kit (Qiagen, Hilden, Germany) and sequenced using the Bigdye_Terminator Sequences were compared with the normal PML and RARA sequences (GenBank accession numbers: NM_033238.2; NM_000964.3).
Based on the sequence of the atypical PML/RARA transcripts, patient-specific forward primers were designed (Table 1) specific PML/RARA copy number. In UPN 43, for which the DNA was available at diagnosis, we performed a long-range nested PCR strategy followed by direct DNA sequencing to identify the exact location of the break points at PML and RARA loci. 20 DNA was purified with the QIAamp DNA mini kit (Qiagen, Hilden, Germany). The patient genomic Table 2 .
In UPN 5, conventional RT-PCR amplification for the bcr1 fusion product (381 bp) showed a smaller product (180 bp) ( Figure 1A ), whereas two different PCR products (649 and 505 bp) were obtained using primers for bcr3 amplification ( Figure 1B) . 5 In UPN 31, a band of 567 bp, larger than the expected 376 bp, was amplified using bcr3 primers ( Figure 1B) . In UPN 43, conventional RT-PCR using primers for bcr1 resulted in two products of 474 and 327 bp ( Figure 1A 3.2 | Conventional and patient-specific Q-RT-PCR for molecular MRD monitoring PML/RARA expression was then analyzed in serial follow-up samples for UPN 5, 31, and 43 (median of 10 samples/patient, range 8-13) by a specifically designed Q-RT-PCR and by conventional assays. 6 Sensitivity and specificity of each patient-specific assay are shown in Table 1 . The coefficients of the standard curves for the three assays 
